Integrated Biopharma spins off biotech company

New Jersey-based nutraceutical company Integrated Biopharma is spinning off its interest in iBioPharma to form a stand-alone biotech company. Chairman and CEO E. Gerald Kay said that iBioPharma will be able to raise capital and make pacts with other companies more effectively as a stand-alone than as a subsidiary of Integrated Biopharma. "We strongly believe in the long-term value of the propriety intellectual property developed and owned by iBioPharma, particularly in the growing area of vaccines and therapeutic proteins."

- check out this release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.